In the present study, we identified that high HSP90α was associated with poor PFS and OS in advanced lung cancer patients treated with PD-1/PD-L1 inhibitors plus chemotherapy after adjusting other covariates, suggesting that plasmatic levels of HSP90α at diagnosis may serve as a promising prognostic indicator in clinical practice. This evidence concerns the gene PDCD1 and lung cancer.